Debt-to-equity of Enliven Therapeutics, Inc. from 30 Sep 2020 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Enliven Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2020 to 31 Dec 2025.
  • Enliven Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 3.6%, a 46% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Enliven Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 3.6% -3% -46% 31 Dec 2025
Q3 2025 3.9% -3.9% -50% 30 Sep 2025
Q2 2025 4.6% -3% -40% 30 Jun 2025
Q1 2025 5.8% -0.78% -12% 31 Mar 2025
Q4 2024 6.6% +1.1% +19% 31 Dec 2024
Q3 2024 7.8% +2% +35% 30 Sep 2024
Q2 2024 7.6% -0.23% -3% 30 Jun 2024
Q1 2024 6.6% -24% -79% 31 Mar 2024
Q4 2023 5.5% +15% 31 Dec 2023
Q3 2023 5.8% +15% 30 Sep 2023
Q2 2023 7.8% +58% 30 Jun 2023
Q1 2023 31% -13% -29% 31 Mar 2023
Q4 2022 -9.7% -24% -169% 31 Dec 2022
Q3 2022 -9.4% -22% -175% 30 Sep 2022
Q2 2022 -50% -62% -525% 30 Jun 2022
Q1 2022 43% +35% +385% 31 Mar 2022
Q4 2021 14% +6.4% +82% 31 Dec 2021
Q3 2021 13% +4.8% +62% 30 Sep 2021
Q2 2021 12% 30 Jun 2021
Q1 2021 9% 31 Mar 2021
Q4 2020 7.7% 31 Dec 2020
Q3 2020 7.8% 30 Sep 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.